Kinnate Biopharma Inc. KNTE
2.65 0.00 (+0.00%)
At closeApr 2, 2024, 4:00 PM EDT
2.64 Day range 2.68
52-week range unavailable
- Market cap
- 124.99M
- Shares out
- 47.17M
- Forward P/E
- -2.55
- Volume
- 2.12M
- Open
- 2.65
- Previous close
- 2.65
- Day's range
- 2.64 – 2.68
- Beta
- 1.34
- Analysts
- Buy
- Price target
- 2.36 (-10.9%)
- Earnings date
- May 9, 2024
No chart data for this range yet.
Key statistics
- Enterprise value
- -38.87M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.72
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -59.61M
- Total cash
- 167.58M
- Total debt
- 3.38M
- Return on equity
- -55.80%
- Short % of float
- 1.55%
- 50-day average
- 2.49
- 200-day average
- 2.24
Analyst view
Consensus: buy
Buy
Price target (mean) 2.36 -10.9% downside
Now 2.65
- Target (low)
- 2.00
- Target (mean)
- 2.36
- Target (high)
- 2.59
Ratings (-1m) 7 3 buy · 4 hold · 0 sell
- Strong buy3
- Buy0
- Hold4
- Sell0
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate -0.34.
Financials — quick view
KNTE Revenue — quarterly 0
KNTE Net income — quarterly -17.06M
KNTE EPS — quarterly -0.36
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | -0.36 | — | — | — |
| Apr 3, 2024 | Dec 1, 2023 | -0.45 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.69 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | -0.76 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.73 | — | — | — |
| Mar 15, 2023 | Dec 1, 2022 | -0.70 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2023 | Jefferies | main | Buy | Buy |
| Sep 18, 2023 | Wedbush | down | Outperform | Neutral |
| Sep 18, 2023 | HC Wainwright & Co. | down | Buy | Neutral |
| Sep 18, 2023 | Piper Sandler | down | Overweight | Neutral |
| Aug 14, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 7, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a clinical-stage oncology company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kinnate.com
News
KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE 
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories 
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, Exarafenib, to Pierre Fabre Laboratories 
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: What Does It Mean for the Stock? 
KINNATE BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTE 
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kinnate Biopharma Inc. 
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA 
KNTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kinnate Biopharma Inc. Is Fair to Shareholders 
Kinnate Biopharma Inc. Enters into Agreement to be Acquired by XOMA Corporation for Between $2.3352 and $2.5879 Per Share in Cash, Plus One Contingent Value Right per Share 
Kinnate Biopharma Inc. Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Your note
Sign in to keep a note on KNTE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FORESITE CAPITAL MANAGEMENT IV, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2023 | 0 |
| GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 4, 2023 | 0 |
| KRISHNAMOHAN NEHA | Chief Financial Officer | Stock Award(Grant) | Aug 31, 2022 | 69,015 |
| MELTZ MARK A. | Chief Operating Officer | Stock Award(Grant) | Aug 31, 2022 | 28,465 |
| ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 4, 2023 | 0 |
| TANANBAUM JAMES B | Director and Beneficial Owner of more than 10% of a Class of Security | Purchase | May 7, 2023 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Foresite Capital Management IV, LLC | 20.54% | 9,671,643 | 29.31M | Jun 29, 2023 |
| Orbimed Advisors LLC. | 17.01% | 8,009,729 | 24.27M | Jun 29, 2023 |
| Foresite Capital Management V, LLC | 7.49% | 3,525,957 | 10.68M | Jun 29, 2023 |
| Nextech Invest Ag | 4.95% | 2,329,480 | 7.06M | Jun 29, 2023 |
| Vida Ventures Advisors, LLC | 4.69% | 2,207,772 | 3.09M | Sep 29, 2023 |
| Lynx1 Capital Management Lp | 4.35% | 2,048,736 | 6.21M | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.55% | 730,663 | 2.21M | Jun 29, 2023 |
| Fidelity Select Portfolios - Biotechnology | 0.75% | 351,780 | 784.47K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.46% | 215,647 | 653.41K | Jun 29, 2023 |
| BlackRock Health Sciences Term Trust | 0.42% | 196,773 | 596.22K | Jun 29, 2023 |
| iShares NASDAQ Biotechnology ETF | 0.30% | 139,853 | 311.87K | Aug 30, 2023 |
| Fidelity Extended Market Index Fund | 0.17% | 78,551 | 337.77K | May 30, 2023 |